Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

作者：Kaichun Wu, Changqing Zheng, Qian Cao, Yijuan Ding, Xiang Gao, Jie Zhong, Cheng‐Tang Chiu, Hu Zhang, Xin Wang, Bangmao Wang, Jie Liang, Xiaowei Liu, Yongjian Zhou, Baohong Xu, Tae-Oh Kim, Xizhong Shen, Dongfeng Chen, Weichang Chen, Yulan Liu, Jun Shen, Fei Liu, Xiaoyun Ding, Qiang Zhan, Jen‐Wei Chou, Sandra Zeng, Yunfeng Lin, Lisa Ying, Xia Chen, Zhe Zhang, Ning Wang, Xiaocang Cao, Lingna Ye, Qinwen Huang, Hairong Zhang, Hongjie Zhang, Zhenyu Zhang, Xiaohua Hou, Huahong Wang, Jinhai Wang, Feng Pan, Mei Liu, Fangyu Wang, Deliang Liu, Wensheng Pan, Qizhi Wang, Jin Ding, K. B. Kim, Eun Soo Kim, Feng Xu, Kaiguang Zhang, Yisen Huang, Jiangbin Wang, Yadong Lai, Ling Zhang, Hsu‐Heng Yen, Wei Wu, Chenggong Yu, Chiyi He, Baisui Feng, Tien-Yu Huang · 发表于：˜The œLancet. Gastroenterology & hepatology · 年份：2025 · DOI：10.1016/s2468-1253(25)00198-0 · 被引用次数：8 · 研究领域：Inflammatory Bowel Disease、Sphingolipid Metabolism and Signaling、Rheumatoid Arthritis Research and Therapies